HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia

HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia

Abstract Background Infants diagnosed with B cell acute lymphoblastic leukemia (B-ALL) and t(4;11) chromosomal rearrangement display poor therapeutic response, associated to the low expression of B lymphocyte factor HDAC7. This study was conceived to identify a therapeutic strategy for t(4;11) B-ALL...

Full description

Saved in:
Bibliographic Details
Main Authors: Oriol de Barrios, Ingrid Ocón-Gabarró, Mar Gusi-Vives, Olga Collazo, Ainara Meler, Paola A. Romecín, Alba Martínez-Moreno, Juan Ramón Tejedor, Mario F. Fraga, Pauline Schneider, Michela Bardini, Giovanni Cazzaniga, Rolf Marschalek, Ronald W. Stam, Clara Bueno, Pablo Menéndez, Maribel Parra
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Biomarker Research
Subjects:
Infant t(4;11) B-ALL
HDAC7
Combinatorial therapy
Menin-1 inhibitors
Online Access:https://doi.org/10.1186/s40364-025-00810-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-025-00810-1

Similar Items